1112 related articles for article (PubMed ID: 30624031)
1. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
3. Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.
Volkmann ER; Tashkin DP; Kuwana M; Li N; Roth MD; Charles J; Hant FN; Bogatkevich GS; Akter T; Kim G; Goldin J; Khanna D; Clements PJ; Furst DE; Elashoff RM; Silver RM; Assassi S
Arthritis Rheumatol; 2019 Dec; 71(12):2059-2067. PubMed ID: 31233287
[TBL] [Abstract][Full Text] [Related]
4. Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease.
Avouac J; Cauvet A; Steelandt A; Shirai Y; Elhai M; Kuwana M; Distler O; Allanore Y
PLoS One; 2020; 15(5):e0232978. PubMed ID: 32384128
[TBL] [Abstract][Full Text] [Related]
5. Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis?
Elhaj M; Charles J; Pedroza C; Liu X; Zhou X; Estrada-Y-Martin RM; Gonzalez EB; Lewis DE; Draeger HT; Kim S; Arnett FC; Mayes MD; Assassi S
J Rheumatol; 2013 Jul; 40(7):1114-20. PubMed ID: 23588945
[TBL] [Abstract][Full Text] [Related]
6. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma.
Hant FN; Ludwicka-Bradley A; Wang HJ; Li N; Elashoff R; Tashkin DP; Silver RM;
J Rheumatol; 2009 Apr; 36(4):773-80. PubMed ID: 19286849
[TBL] [Abstract][Full Text] [Related]
7. Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease.
Kuwana M; Shirai Y; Takeuchi T
J Rheumatol; 2016 Oct; 43(10):1825-1831. PubMed ID: 27481907
[TBL] [Abstract][Full Text] [Related]
8. KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).
Sieiro Santos C; Antolín SC; Lorenzo JC; Garay CL; Morales CM; de Miguel EB; Guerrero MR; Herránz LS; Álvarez ED
Semin Arthritis Rheum; 2024 Apr; 65():152366. PubMed ID: 38290372
[TBL] [Abstract][Full Text] [Related]
9. KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease.
Salazar GA; Kuwana M; Wu M; Estrada-Y-Martin RM; Ying J; Charles J; Mayes MD; Assassi S
J Rheumatol; 2018 Aug; 45(8):1153-1158. PubMed ID: 29961690
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis.
Kennedy B; Branagan P; Moloney F; Haroon M; O'Connell OJ; O'Connor TM; O'Regan K; Harney S; Henry MT
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):228-36. PubMed ID: 26422568
[TBL] [Abstract][Full Text] [Related]
11. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement.
Bonella F; Volpe A; Caramaschi P; Nava C; Ferrari P; Schenk K; Ohshimo S; Costabel U; Ferrari M
Sarcoidosis Vasc Diffuse Lung Dis; 2011 Jul; 28(1):27-33. PubMed ID: 21796888
[TBL] [Abstract][Full Text] [Related]
12. High Level of Chemokine CCL18 Is Associated With Pulmonary Function Deterioration, Lung Fibrosis Progression, and Reduced Survival in Systemic Sclerosis.
Hoffmann-Vold AM; Tennøe AH; Garen T; Midtvedt Ø; Abraityte A; Aaløkken TM; Lund MB; Brunborg C; Aukrust P; Ueland T; Molberg Ø
Chest; 2016 Aug; 150(2):299-306. PubMed ID: 26997242
[TBL] [Abstract][Full Text] [Related]
13. Follow-up of serum KL-6 lung fibrosis biomarker levels in 173 patients with systemic sclerosis.
Kumánovics G; Görbe E; Minier T; Simon D; Berki T; Czirják L
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-138-44. PubMed ID: 24773853
[TBL] [Abstract][Full Text] [Related]
14. Kinetic changes in serum KL-6 levels predict disease progression in patients with systemic sclerosis-associated interstitial lung disease.
Watanabe S; Kase K; Saeki K; Ohkura N; Murata A; Waseda Y; Takato H; Ichikawa Y; Yasui M; Kasahara K
Respir Med; 2022 Jan; 191():106689. PubMed ID: 34844174
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort.
Cao XY; Hu SS; Xu D; Li MT; Wang Q; Hou Y; Zeng XF
Int J Rheum Dis; 2019 Jan; 22(1):108-115. PubMed ID: 30592376
[TBL] [Abstract][Full Text] [Related]
16. Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational study.
Sumida H; Asano Y; Tamaki Z; Aozasa N; Taniguchi T; Toyama T; Takahashi T; Ichimura Y; Noda S; Akamata K; Saigusa R; Miyazaki M; Kuwano Y; Yanaba K; Yoshizaki A; Sato S
J Dermatol; 2018 Dec; 45(12):1425-1433. PubMed ID: 30289572
[TBL] [Abstract][Full Text] [Related]
17. Serum concentration of surfactant protein D in patients with systemic sclerosis: The potential marker of the interstitial lung disease severity.
Grosicka A; Manasar A; Kucharz EJ; Kotyla PJ
Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):541-549. PubMed ID: 31174823
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis.
Kumánovics G; Minier T; Radics J; Pálinkás L; Berki T; Czirják L
Clin Exp Rheumatol; 2008; 26(3):414-20. PubMed ID: 18578962
[TBL] [Abstract][Full Text] [Related]
19. Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study.
Xue C; Wu N; Li X; Qiu M; Du X; Ye Q
BMC Pulm Med; 2017 Nov; 17(1):144. PubMed ID: 29149883
[TBL] [Abstract][Full Text] [Related]
20. Performance of serum biomarkers reflective of different pathogenic processes in systemic sclerosis-associated interstitial lung disease.
Györfi AH; Filla T; Dickel N; Möller F; Li YN; Bergmann C; Matei AE; Harrer T; Kunz M; Schett G; Distler JHW
Rheumatology (Oxford); 2024 Apr; 63(4):962-969. PubMed ID: 37421394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]